Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.
The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.